Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome.

The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Molecular vision (Impact Factor: 1.99). 02/2009; 15:955-61.
Source: PubMed

ABSTRACT The polymorphisms of the Fc receptor-like 3 gene (FCRL3), a novel immunoregulatory gene, have been shown to be associated with certain autoimmune diseases. This study was designed to examine whether the polymorphisms of FCRL3 are associated with susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Chinese population.
A case-control study was performed in 230 Chinese VKH patients and 301 healthy controls. Four single nucleotide polymorphisms (SNPs; -169C/T, -110A/G, +358C/G, and +1381A/G) in FCRL3 were detected using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). human leukocyte antigen -DR4 (HLA-DR4) and HLA-DRw53 genotyping was performed using PCR techniques.
The results showed that the frequency of haplotype CACG was significantly lower in patients when compared with that in controls (p=0.0018, corrected p [pc]=0.0288). A significantly higher frequency was found for haplotype CGGG in HLA-DR4 negative patients than in HLA-DR4 negative controls (p=9.94 x 10(-8), Pc=1.59 x 10(-6)). There were no significant differences in the allele and genotype frequencies of the four investigated SNPs between VKH patients and controls. HLA-DR4 and HLA-DRw53 were significantly associated with VKH syndrome (p=3.21 x 10(-16) and p=7.08 x 10(-5), respectively). Stratification analysis according to HLA-DR4 and HLA-DRw53 did not show any association of FCRL3 polymorphisms with VKH syndrome.
Our study confirms the previous association of HLA-DR4 and HLA-DRw53 with VKH syndrome but fails to demonstrate an association between FCRL3 polymorphisms and VKH syndrome. Haplotype CACG might be a protective haplotype for VKH syndrome, and haplotype CGGG may be a risk haplotype in HLA-DR4 negative individuals.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Polymorphisms of interleukin-23 receptor (IL23R) gene have recently been reported to be associated with the susceptibility to several immune-related diseases. The aim of this study was to determine the association of IL23R polymorphisms with Vogt-Koyanagi-Harada (VKH) syndrome, a disease presumably mediated by autoimmune response. A total of 382 Chinese Han patients with VKH syndrome and 407 healthy controls were genotyped by the polymerase chain reaction-restriction fragment length polymorphism method. Data were analyzed by chi(2) analysis. All genotype distributions in healthy controls were in Hardy-Weinberg equilibrium. There was no difference among the investigated four single nucleotide polymorphisms concerning the linkage disequilibrium between the tested samples and those available in the international HapMap. The genotype and allele frequencies of rs17375018, rs7517847, rs11209032, and rs1343151 were not different between patients with VKH syndrome and healthy controls. Analysis according to gender and clinical findings did not show any association of the four polymorphisms with these parameters. In conclusion, the tested IL23R gene polymorphisms are not associated with the susceptibility to VKH syndrome in the Chinese Han population.
    Human immunology 04/2010; 71(4):414-7. · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review current advances in the diagnosis and therapy of Vogt-Koyanagi-Harada (VKH) disease. A new T-cell subset (Th17) may play an important role in the initiation and maintenance of inflammatory disease when stimulated by the interleukin (IL)-23, thus producing IL-17. Recent developments of new imaging techniques, such as high-resolution optical coherence tomography 3 scanner (OCT3), have allowed greater accuracy in VKH disease diagnosis. The OCT3 examinations have shown that cystoid spaces appear in the neurosensory layer (between the inner and outer segments of photoreceptors) and not in the subretinal space. This structural finding was also supported by functional studies with multifocal electroretinography that measured the photoreceptors activity. Antimetabolites (azathioprine, mycophenolate mofetil and methotrexate), T-cell inhibitors (cyclosporine and tacrolimus) and biologic agents, associated with the well known glucocorticosteroids therapy, showed good results in acute and chronic phases of the disease. Intravitreal triamcinolone and bevacizumab were reported to have encouraging results for progressive or stubborn cases of VKH disease. To uphold visual acuity, an early, fast and accurate diagnosis is necessary, followed by an aggressive and lengthy immunosuppressive treatment.
    Current opinion in ophthalmology 11/2010; 21(6):430-5. · 2.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to identify the causes of the nonadherence (NA) of German patients to their prescribed medication. In the course of the investigation, the NA risk profiles resulting from the combination of the various causes were identified. Two cross-sectional surveys with a total of 1517 patients (comprising 1177 patients contacted by telephone and forming survey 1 and a different set of 340 patients interviewed in-depth and face-to-face forming survey 2) were conducted. Self-reported NA was measured by the generic Morisky Medication Adherence Scale (MMAS). Survey 1 used a four-item MMAS and Survey 2 an eight-item MMAS. Approximately 35% to 40% of the patients can be described as nonadherent. In survey 1, a few causes explain the NA (chronic disease, younger age, and fewer medications required to be taken). The more detailed survey 2 shows that the existence of intentional NA has considerably more influence than any other causal factors. Positive medication beliefs, a positive mood, and a good patient-doctor relationship reduce the NA risk. Furthermore, patients who are easily able to recognize the correct medication, as evidenced by ability to correctly identify the packaging, have a reduced NA probability. Concerning additive risk, patients who are chronically ill but display no other causes of risk have an NA probability of 10.4%. By contrast, in patients displaying all the identified causes of risk, the rate increases to 93.9%. About one-third of patients can be classified as nonadherent. Intentional/medication-based NA causal factors explain the NA considerably better than do socioeconomics. The existence of more than one cause of risk considerably increases the NA risk of a patient.
    Value in Health 12/2011; 14(8):1092-100. · 2.19 Impact Factor


1 Download
Available from